Scientific Presentations

2022

VRDN-001, A Potent and Selective Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease (TED): Phase 1 Safety and Pharmacodynamic Results in Healthy Volunteers

American Thyroid Association (ATA) 2022 Annual Meeting

October 22, 2022

VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) for Thyroid Eye Disease (TED): Phase 1/2 Proof of Concept in Patients with TED

American Thyroid Association (ATA) 2022 Annual Meeting

October 21, 2022

VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab

American Thyroid Association (ATA) 2022 Annual Meeting

October 20, 2022

2021

Characterization of VRDN-001, a High Affinity and Potent anti-IGF-1R Inhibitory Antibody for the Treatment of Thyroid Eye Disease

American Thyroid Association (ATA) 2021 Annual Meeting

October 2, 2021

VRDN-002, A Second-Generation Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody for TED: Preclinical PK Profile and Clinical Promise

American Thyroid Association (ATA) 2021 Annual Meeting

September 30, 2021